Omid C. Farokhzad
奥米德·法罗赫扎德
MD
Professor of Anesthesiology; Founder & CEO, Seer Bio麻醉学教授；Seer Bio创始人兼首席执行官
👥Biography 个人简介
Pioneer in translating targeted nanoparticles from bench to clinic, especially PSMA-targeted nanoparticles for prostate cancer. Co-founded BIND Biosciences (first targeted nanoparticle company to reach clinical trials) and multiple biotech ventures. Known for aptamer-conjugated PLGA-PEG nanoparticles.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
PSMA-Targeted Nanoparticles for Prostate Cancer
Engineered aptamer-functionalized PLGA-PEG nanoparticles targeting PSMA on prostate cancer cells, achieving selective tumor accumulation and enhanced docetaxel delivery in preclinical and early clinical models.
Nanoparticle Clinical Translation
Co-founded BIND Biosciences to translate targeted nanoparticle technology into clinical-stage oncology candidates, demonstrating feasibility of precision nanomedicine in human trials.
Representative Works 代表性著作
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
PNAS (2006)
Seminal study demonstrating aptamer-targeted nanoparticles delivering docetaxel selectively to PSMA-expressing prostate tumors in vivo.
Controlled Release of siRNA Using Lipid-Like Nanoparticles
ACS Nano (2012)
Demonstrated efficient siRNA delivery using optimized lipid nanoparticles, advancing RNA-based cancer therapeutics.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 奥米德·法罗赫扎德 的研究动态
Follow Omid C. Farokhzad's research updates
留下邮箱，当我们发布与 Omid C. Farokhzad（Harvard Medical School / Brigham and Women's Hospital）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment